Verge Genomics, Eli Lilly partner to develop ALS therapies
Verge Genomics has announced a three-year partnership with Eli Lilly and Company to discover and develop novel therapies for amyotrophic lateral sclerosis (ALS), a motor neuron disease.
Verge Genomics has announced a three-year partnership with Eli Lilly and Company to discover and develop novel therapies for amyotrophic lateral sclerosis (ALS), a motor neuron disease.
The Russian Direct Investment Fund (RDIF) has announced the production of a test batch of the Russian Covid-19 vaccine, Sputnik V, in Mexico.
Philip Morris International has signed an agreement to acquire Fertin Pharma from private equity firm EQT for approximately $812.8m (DKK5.1bn).
The International Finance Corporation (IFC) has announced a joint financing package of $712.67m (€600m) for Aspen Pharmacare to support the Covid-19 vaccines production.
Spanish healthcare company Grifols announced that Singapore's wealth fund GIC agreed to invest about $1bn in Grifols’ wholly owned US subsidiary Biomat USA.
Pharmaceutical company Indivior has collaborated with French biotechnology company Aelis Farma to advance the clinical development of a treatment for cannabis use disorder (CUD) and cannabis-induced psychosis (CIP).
South Korean drug manufacturer Samsung Biologics is planning to expand its portfolio of services by adding a mRNA vaccine drug substance (DS) manufacturing line at its facility in Songdo, Seoul.
Biopharmaceutical company CANbridge Pharmaceuticals has signed a licensing agreement with Mirum Pharmaceuticals for the development and commercialisation of maralixibat in Greater China.
GlaxoSmithKline and Vir Biotechnology have announced the European Medicines Agency (EMA) review of VIR-7831 (GSK4182136) for the early treatment of Covid-19.
Takeda Pharmaceutical Company has completed the previously announced sale of a portfolio of select over-the-counter (OTC) pharma products and non-core assets to Orifarm Group for $670m.